Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, et al.
OncoImmunology (2019) Vol. 8, Iss. 4, pp. e1554969-e1554969
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
Giovanni Fucá, Romain Cohen, Sara Lonardi, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 2, pp. e004001-e004001
Open Access | Times Cited: 74
Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion
Yang Liu, Lulu Wang, Qianqian Song, et al.
Nature Nanotechnology (2021) Vol. 17, Iss. 2, pp. 206-216
Open Access | Times Cited: 73
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
Iris K. Lee, Estela Noguera-Ortega, Zebin Xiao, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 24, pp. 5330-5342
Open Access | Times Cited: 31
C1q+tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion
Siyu Zhang, Wen‐Bei Peng, Haolei Wang, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 8, pp. e007441-e007441
Open Access | Times Cited: 17
Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications
Ge Shan, Yuwei Zhao, Jun Liang, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients
Nicola Fusco, Valentina Vaira, I. Righi, et al.
Lung Cancer (2020) Vol. 150, pp. 53-61
Closed Access | Times Cited: 39
Translational Nanotherapeutics Reprograms Immune Microenvironment in Malignant Pleural Effusion of Lung Adenocarcinoma
Zhenhuan Song, Weizhan Luo, Haichong Zheng, et al.
Advanced Healthcare Materials (2021) Vol. 10, Iss. 12
Closed Access | Times Cited: 38
Single-cell analysis of diverse immune phenotypes in malignant pleural effusion
Zhong‐Yin Huang, Ming‐Ming Shao, Jianchu Zhang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 36
Altered phenotypic and metabolic characteristics of FOXP3 + CD3 + CD56 + natural killer T (NKT)-like cells in human malignant pleural effusion
Zi-Hao Wang, Pei Zhang, Wen‐Bei Peng, et al.
OncoImmunology (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 23
Immunotherapeutic hydrogel for co-delivery of STAT3 siRNA liposomes and lidocaine hydrochloride for postoperative comprehensive management of NSCLC in a single application
Xianglei Fu, Yanbin Shi, Zili Gu, et al.
Asian Journal of Pharmaceutical Sciences (2024) Vol. 19, Iss. 3, pp. 100925-100925
Open Access | Times Cited: 4
Development and validation of a novel scoring system developed from a nomogram to identify malignant pleural effusion
Sufei Wang, Shan Tian, Yuan Li, et al.
EBioMedicine (2020) Vol. 58, pp. 102924-102924
Open Access | Times Cited: 36
Diagnosis and Management of Malignant Pleural Effusion: A Decade in Review
Blake Jacobs, Ghias Sheikh, Houssein Youness, et al.
Diagnostics (2022) Vol. 12, Iss. 4, pp. 1016-1016
Open Access | Times Cited: 19
Malignant pleural effusion management: keeping the flood gates shut
Steven Walker, Rachel Mercer, Nick Maskell, et al.
The Lancet Respiratory Medicine (2019) Vol. 8, Iss. 6, pp. 609-618
Open Access | Times Cited: 31
Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis
Linlin Ye, Wen‐Bei Peng, Yiran Niu, et al.
Annals of Translational Medicine (2020) Vol. 8, Iss. 24, pp. 1647-1647
Open Access | Times Cited: 23
Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion
Yiran Niu, Qiong Zhou
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 4
Closed Access | Times Cited: 14
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
Giovanni Randon, Yu Aoki, Romain Cohen, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e007104-e007104
Open Access | Times Cited: 8
Enzyme-Dynamic Extracellular Vesicles for Metalloimmunotherapy of Malignant Pleural Effusions
Jiexin Li, Ruiqi Yang, Fuqiang Dong, et al.
ACS Nano (2024) Vol. 18, Iss. 33, pp. 21855-21872
Closed Access | Times Cited: 2
Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?
Nicola Principe, Joel Kidman, Richard Lake, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 18
Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
Francesca Napoli, Angela Listì, Vanessa Zambelli, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2564-2564
Open Access | Times Cited: 18
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study
Nicolas Epaillard, José Carlos Benítez, Teresa Gorría, et al.
Lung Cancer (2021) Vol. 155, pp. 114-119
Open Access | Times Cited: 17
Novel and Future Treatment Options in Mesothelioma: A Systematic Review
Danijela Štrbac, Vita Dolžan
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 1975-1975
Open Access | Times Cited: 11
Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion
Xinying Li, Guannan Wu, Cen Chen, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 14
Intrapleural interleukin-2–expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease
Chigozirim N. Ekeke, Kira L. Russell, Pranav Murthy, et al.
Journal of Thoracic and Cardiovascular Surgery (2020) Vol. 163, Iss. 4, pp. e313-e328
Open Access | Times Cited: 15
Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies
Chigozirim N. Ekeke, Kira L. Russell, Kyla Joubert, et al.
Annals of Surgical Oncology (2021) Vol. 28, Iss. 5, pp. 2715-2727
Open Access | Times Cited: 13
IL-26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4+IL-22+ T-cell differentiation and inhibiting CD8+ T-cell cytotoxicity
Yiran Niu, Linlin Ye, Wen‐Bei Peng, et al.
Journal of Leukocyte Biology (2021) Vol. 110, Iss. 1, pp. 39-52
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top